119618-21-2

119618-21-2 structure

Name: (R)-N-METHYL-1-[3,5-BIS(TRIFLUOROMETHYL)PHENYL]ETHYLAMINE
Chemical Name: (r)-oxybutynin chloride
CAS Number: 119618-21-2
Molecular Formula: C₂₂H₃₂ClNO₃
Molecular Weight: 393.94700
Catalog: Signaling Pathways GPCR/G Protein mAChR
Create Date: 2017-07-02 06:32:17
Modify Date: 2025-08-25 17:26:48
(R)-Oxybutynin (Aroxybutynin), a (R)-isomer of Oxybutynin, is an orally active muscarinic receptor antagonist. (R)-Oxybutynin has antimuscarinic, antispasmodic and anticholinergic activity, competitively antagonizes Carbachol-induced contractions. (R)-Oxybutynin can be used for researching incontinence due to neurogenic bladder dysfunction[1][2][3].

Name	(r)-oxybutynin chloride
Synonyms	Benzeneacetic acid,a-cyclohexyl-a-hydroxy-,4-(diethylamino)-2-butynyl ester,(aR)-(9CI) (R)-A-PHENYLCYCLOHEXANEGLYCOLIC ACID 4-(DIETHYLAMINO)-2-BUTYNYL ESTER,HYDROCHLORIDE [3H]-Oxybutynin (R)-OXYBUTYNIN HCL (R)-Oxybutynin Benzeneacetic acid,a-cyclohexyl-a-hydroxy-,4-(diethylamino)-2-butynyl ester,(R) (R)-Oxybutynin hydrochloride

Description	(R)-Oxybutynin (Aroxybutynin), a (R)-isomer of Oxybutynin, is an orally active muscarinic receptor antagonist. (R)-Oxybutynin has antimuscarinic, antispasmodic and anticholinergic activity, competitively antagonizes Carbachol-induced contractions. (R)-Oxybutynin can be used for researching incontinence due to neurogenic bladder dysfunction[1][2][3].
Related Catalog	Signaling Pathways >> Neuronal Signaling >> mAChR Signaling Pathways >> GPCR/G Protein >> mAChR Research Areas >> Neurological Disease
Target	Muscarinic receptor, mAChR[1][2]
References	[1]. Smith ER, et al. Comparison of the antimuscarinic and antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of racemic terodiline. Arzneimittelforschung. 1998 Oct;48(10):1012-8. [2]. Siddiqui MA, et al. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs. 2004;64(8):885-912. [3]. Zobrist RH, et al. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res. 2001 Jul;18(7):1029-34.